

8. Literaturverzeichnis

1. Adamek, R. J., Freitag, M., Opferkuch, W., Ruhl, G. H., Wegner, M. (1996): „Duration of the therapy plays a decisive role in H.pylori eradication using omeprazole and amoxicillin“, *American Journal of Gastroenterology*, 89: 136-138
2. Adamek, R. J., Freitag, M., Opferkuch, W. et al. (1994): „Intravenous omeprazole / amoxicillin combination therapy in patients with Helicobacter pylori positive acute peptic ulcer bleeding“, *Scandinavian Journal of Gastroenterology*, 29: 880–883
3. Andersson, T., Andren, K., Cederberg, C., Lagerström, P. O., Lundborg, P., Sänberg, I. (1990): „Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects“, *British Journal of Clinical Pharmacology*, 29: 557–563
4. Andersson, T., Bergstrand, R., Cederberg, C. (1991): „Influence of acid secretory status on absorption of omeprazole from enteric coated granules“, *British Journal of Clinical Pharmacology*, 31: 275–278
5. Andersson, T., Cederberg, C., Heggelund, A., Lundborg, P. (1991): „The pharmacokinetics of single and repeated once daily doses of 10, 20 and 40 mg Omeprazole as enteric-coated granula“, *Drug Investigation*, 3: 45–52
6. Andersson, T., Lundborg, P., Regardh, C.-G. (1991): „Lack of effect of omeprazole treatment on steadystate plasma levels of metoprolol“, *European Journal of Clinical Pharmacology*, 40: 61–65
7. Andersson, T. und C.-G. Regardh (1990): „Pharmacokinetics of omeprazole and metabolites following single intravenous and oral doses of 40mg and 80mg“, *Drug Investigation*, 2: 255–263
8. Angerer, M., Koelzow, H., Londong, W. (1990): „Simultaneous comparison of 24 hours intragastric pH-recording using glass and antimony electrodes in man“, *Digestive Disease*, 8: 38–45
9. Armstrong, D., Emde, C., Blum, A. (1987): „Review twentyfour hour intragastric pH-metry in man. Current status and recommendations“, *Gut*, 23: 1177–1188
10. Armstrong, D., Verdù, E., Fraser, R., Viani, F., Idström, J.-P., Cederberg, C., Blum, A. L.(1993): „Helicobacter pylori infection augments the antisecretory effect of omeprazole“, *Acta Gastroenterology Belgium*, 56: 129

11. Barr, W. H. und E. M. Zola (1994): „Differential absorption of amoxicillin from the human small and large intestine“, *Clinical Pharmacology and Therapeutics*, 9: 279–285
12. Bates, R. G.: *Determination of pH: Theory and practice*, Wiley & Son, New York 1964: S.44-45
13. Bathia, S. J., Kochar, N., Abraham, P., Nair, N. G., Mehta, A. P. (1989, Oktober): „Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro“, *Journal of Clinical Microbiology*, 27: 2328–2330
14. Bauer, K., Hiltmann, R., Schmid, J., Aughagen, E. (1956): *Medizin und Chemie*, 5:25
15. Bauerfeind, P., Cilluffo, T., Fimmel, C. J., Gasser, T., Köhler, W., Merki, H., Emde, C., Etienne, A., Blum, A. I. (1985): „Die intragastrale Langzeit-pH-Metrie“, *Schweizerisch medizinische Wochenschrift*, 115: 1630–1641
16. Bayerdörffer, E., Mannes, G. A., Sommer, A., Höchtler, J., Weingart, R., Hatz, R. et al. (1993): „Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxicillin“, *Scandinavian Journal of Gastroenterology*, 28: 19–25
17. Bayerdörffer, E., Mannes, G. A., Sommer, A. et al. (1992): „High dose omeprazole treatment combined with amoxicillin eradicates H.pylori“, *Gastroenterology*, 104: 38-39
18. Bayerdörffer, E., Miehke, S, Mannes, GA et al. (1995) „ Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. *Gastroenterology*, 108: 1412-1417
19. Bazzoli, F., Zagari, R. M., Fossi, S., Pozzato, P., Simoni, P., Roda, A. „The 13-C Urea Breath Test for early assessment of Helicobacter pylori eradication“, AGA-Kongress 1995, San Diego (USA), A-961
20. Bazzoli, F., Zagari, R. M., Pozzato, P., Fossi, S. (1994): „13-C Urea Breath Test to quantify Helicobacter pylori colonisation of gastric mucosa and association with severity inflammation“, *American Journal of Gastroenterology*, 89: 8
21. Bell, G. D. und K. U. Powell (1993): „Eradication of Helicobacter pylori and its effect in peptic ulcer disease“, *Scandinavian Journal of Gastroenterology*, 28: 7–11
22. Bell, S. C., Wayne, H. J., Grundy, G., Walton, E. (1969): „Micromethod for assaying serum levels of erythromycin“, *Microbiology*, 1: 88–92

23. Bell, S. M. und R. Wood (1968): „An antibiotic Assay Method“, *Journal of Medical Laboratorial Technology*, 25: 27–32
24. Blume, H. und E. Mutschler (Hrsg.): *Bioäquivalenz – Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel*, GOVI-Verlag, Stuttgart 1991: S.20–32
25. Borody, T. J., Brandl, S., Andrews, P., Ostapowicz, P., Jankiewicz, E. (1992): „High efficacy, low dose triple therapy (TT) for Helicobacter pylori (HP)“, *Gastroenterology*, 102: 44
26. Borody, T. J., Cole, P., Noonan, S., Morgan, A., Ossip, G., Maysay, J., Brandl, S. (1988): „Long-term Campylobacter pylori recurrence post eradication“, *Gastroenterology*, 94: 43
27. Braden, B., Duane, L. P., Caspary, W. F., Lembcke, B. (1984): „More convenient 13-C Urea Breath Test modifications still meet the criteria for valid diagnosis of Helicobacter pylori infection“, *Zeitschrift für Gastroenterologie*, 32: 198–202
28. Brandström, A., Lindberg, P., Junggren, U. (1985): „Structure activity relationships of substituted benzimidazoles“, *Scandinavian Journal of Gastroenterology*, 108: 15–22
29. Brodgan, R. N., Heel, R. C., Speight, T. M., Avery, G. S. (1979): „Amoxicillin injectable: A review of its antibacterial spectrum, pharmacokinetics and therapeutic use“, *Drugs*, 18: 169–184
30. Brodgan, R. N., Speight, T. M., Avery, G. S. (1974): „Amoxicillin: A preliminary report of its pharmacokinetic properties and therapeutic efficacy“, *Drugs*, 7: 326–336
31. Chu-K.M, Choi,H.K, Tuen,H.H et al (1998): „A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori“ *American Journal of Gastroenterology*, 93: 1436-1442
32. Cilluffo, T. S., Armstrong, D., Castiglione, F., Emde, C., Galeazzi, R., Gonvers, J.-J., Blum, A. L (1991): „Reproduzierbarkeit von ambulanten pH-Metrie-Aufzeichnungen im Magen-Korpus und Antrum: Einfluß von Nahrung, Tageszeit und Elektrodenlage“, in: K. H. Fuchs und H. Hamelmann: *Gastrointestinale Funktionsdiagnostik in der Chirurgie*, Blackwell Wissenschaft, Berlin: S.147–167
33. Cortvriendt, W. R. E., Verschoor J. S. C., Hespe. W. (1987): „Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration“, *Drug Research*, 37: 8-12

34. Crabtree, J. E., Tayler, D., Wyatt, J. O., Heatly, R. V. et al. (1991): „Mucosal IgA recognition of *Helicobacter pylori* 120 Kda protein, peptic ulceration and gastric pathology“, *Lancet*, 338: 332–335
35. Creutzfeld, J. (1988): „The achlorhydria-carcinoid sequence: Role of gastrin“, *Digestion*, 39: 61–79
36. Dammann, H.-G., Dreyer, M., Kanagah, R., Wolf, N. (1990): „Gastric aspiration technique for pH-recording: A critical evaluation of this method“, *Digestive Disease*; 1: 3–9
37. Dammann, H.-G., Hoelzer, W., Friedl, W., Müller, P., Simon, B. (1993): „Gastrales Säureprofil über 24 h“, *Deutsche medizinische Wochenschrift*, 108: 600–601
38. Daw, M. A., Deegan, P., Beattie, S., Kean, E., Keane, C. T. et al. (1990): „Suppression of *Helicobacter pylori* during the clinical use of omeprazole“, *Gut*, 31: 1199-1201
39. Daw, M. A., Deegan, P., Leen, E., O’Morain, D. (1991): „Short report: The effect of omeprazole on *Helicobacter pylori* and associated gastritis“, *Alimental Pharmacology Therapy*, 5: 435–439
40. Deakin, M., Ramage, J., Paul, A. et al. (1986): „Effect of enprostil – A synthetic prostaglandin E2 on 24 hour intragastric acidity, nocturnal acid and pepsin secretion“, *Gut*, 27: 1054–1057
41. Delchier, J.-C., Elamine, I., Goldfain, D., Chaussade, S., Barthelemy, P., Idström, J.P. (1996): “Omeprazole-amoxicillin versus omeprazole-amoxicillin-clarithromycin in the eradication of *Helicobacter pylori* “ *Alimental Pharmacology Therapy*, 10: 263-268
42. Deltenre, M., Jonas, C., van Gossum, M., Brugmann, F. (1994): „Omeprazole-amoxicillin and omeprazole-clarithromycin for eradication of *H.pylori*“, *American Journal of Gastroenterology*, 89: 1369-1371
43. Duane, L. P., Braden, B., Lemcke, B., Caspary, W. F. (1994): „C-Urea Breath Test, Serum IgG antibody, gastrin, pepsinogen I and II in patients with or without *Helicobacter pylori* infection“, *American Journal of Gastroenterology*, 89: 433
44. Eggers, R., Kulp, A., Lüdtkke, F.-E., Bauer, F. E. (1990): „Characterization of the C13 Urea Breath test for diagnosis of *Campylobacter pylori* infection“, *Gastroenterology*, 31: 295-300

45. Eggers, R., Kulp, A., Tegeler, R., Lüdtke, F.-E. et al. (1990): „A methodological analysis of the 13 C-Urea Breath test for detection of Helicobacter pylori infections: High sensitivity and specificity within 30 min using 75 mg 13 C-Urea“, *European Journal of Gastroenterology & Hepatology*, 2: 437–444
46. Emde, C., Garner, A., Blum, A. L. (1987): „Progress report. Technical aspects of intraluminal pH-metry in man: Current status and recommendations“, *Gut*, 28: 1177–1188
47. Etienne, A., Fimmel, J., Bron, B. A., Loizeau, E., Blum, A. L. (1985): „Evaluation of pirenzepine on gastric acidity in healthy volunteers using ambulatory 24 hours intragastric pH-metry“, *Gut*, 26: 241–245
48. Fellenius, E., Berglindh, T. et al. (1981): „Substituted benzimidazoles inhibit gastric acidsecretion by blocking H/K-ATP-ase“, *Nature*, 290: 159–161
49. Fimmel, C. J., Etienne, A., Cilluffo, T., von Ritter, C., Gasser, T., Rey, J. P. et al. (1985): „Long-term ambulatory gastric pH-monitoring: Validation of a new method and effect of H₂-receptor antagonists“, *Gastroenterology*, 88: 1842–1851
50. Fiocca, R., Solcia, E., Villani, L., Luinetti, O. (1992, April/Juni): „Pathogenesis of peptic ulcer: Role of Helicobacter pylori gastritis and its course during antibiotic and/or antisecretory treatment“, *Minerva-Gastroenterology-Dietology*, 38: 81–93
51. Fuchs, K. H. und H. Hamelmann: *Gastrointestinale Funktionsdiagnostik in der Chirurgie*, Blackwell Wissenschaft, Berlin 1991: S.123–156
52. Gabryelewski, A., Laszewicz, W., Dzieniszewski, J. et al (1997): „Multicenter evaluation of dual-therapy (omeprazol and amoxicillin) for Helicobacter pylori-associated duodenal and gastric ulcer (two years of the observation)“ *Journal of Physiological Pharmacology*, 48: 93-105
53. Gan, K.H., Geus, W.P., Lamers, C.B.H.W., Heijerman, H.G.M. (1997): „Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H.pylori-negative healthy subjects.“ *Digestive Diseases and Sciences*, 42: 2304-2309
54. Goddard, A.F., Jessa, M.J., Barrett, D.A: et al (1996): „Effect of omeprazole on the distribution of metronidazole, amoxicillin and clarithromycin in human gastric juice.“ *Gastroenterology*, 111: 358-367

55. Goodwin, C. S., Blincow, E., Peterson, G., Sanderson, C., Cheng, W., Marshall, B., Warren, R. J., Mc Culloch, R. (1987): „Enzyme-linked immunosorbent assay for *Campylobacter pyloridis*: Correlation with presence of *C.pyloridis* in the gastric mucosa“, *Journal of Infectious Diseases*, 155: 73–77
56. Goodwin, C. S., Blincow, E. et al. (1986): „The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against *Campylobacter pyloridis*“, *Journal of Antimicrobial Chemotherapy*, 17: 309–314
57. Graham, D. Y., Klein, P. D., Evans, D. J., Evans, D. G., Alpert, L. C., Opekun, A. R., Boutton, T. W. (1987): „*Campylobacter pylori* detected noninvasively by the 13 C Urea Breath Test“, *Lancet*, 1: 1174–1177
58. Graham, D. Y., Klein, P. D., Opekun, A. R., Button, T. W. (1988): „Effect of age and the frequency of active *Campylobacter pylori* infection diagnosed by the C13 Urea Breath Test on normal subjects and patients with peptic ulcer disease“, *Journal of Infectious Diseases*, 155: 177–180
59. Graham, D. Y., Opekun, A., Lew, G., Eban, D. Y., Klein, D. D. (1990): „Application of exaggerate meal stimulated gastrin release in duodenal ulcer patients after clearance of *Helicobacter pylori* infection“, *American Journal of Gastroenterology*, 85: 394-398
60. Graham, D. Y. (1995): „PH-cure of *Helicobacter pylori* infectin: It is difficult to have insights when is in the dark. *American Journal of Gastroenterology*, 90: 674-675
61. Graham, K. S., Malaty, H., el-Zimaity, H. M. et al (1995): „Variability with omeprazole-amoxicillin combinations for treatment of *Helicobacter pylori* infection.“ *American Journal of Gastroenterology*, 90: 1415-1418
62. Granberg, C., Mansikka, A., Lethonen, P.-O., Kujari, H., Grönfors, R., Nurmi, R. I., Stahlberg, M.-R. (1993): „Diagnosis of *Helicobacter pylori* infection by using Pyloriset EIA-G and EIA-A for detection of serum immunoglobulin G (IgG) and IgA antibody“, *Journal of Clinical Microbiology*, 10: 1450–1453
63. Gugler, R. und J. C. Jensen (1987): „Drugs other than H₂-receptor antagonists as clinically important inhibitors of drug metabolism in vivo“, *Pharmacology Therapy*, 33: 133–137
64. Gustavson, L. E., Kaiser, J., Emonds, A. L: et al (1995): „The effect of omeprazole on concentration of Clarithromycin in Plasma and gastric tissue at steady state. *Antimicrob-Agents.Chemoth.*, 39: 2078-83

65. Havu, N. (1986): „Enterochromaffin-like cell carcinoids of gastric mucosa in rats after lifelong inhibition of gastric secretion“, *Digestion*, 35: 42–55
66. Henry, D., Brent, P., Whyte, I., Mihaly, G., Devenish-Meares, S. (1987): „Propranolol steady-state pharmacokinetics are unaltered by omeprazole“, *European Journal of Clinical Pharmacology*, 33: 369–373
67. Hirschl, A., Brandstätter, G., Dragosics, B., Hentschel, E., Kundi, M., Rotter, M. L., Schütze, K., Taufer, M. (1993): „Kinetics of specific IgG antibodies for monitoring the effect of anti-*Helicobacter pylori* chemotherapy“, *Journal of Infectious Diseases*, 168: 763–766
68. Hoffman, K.-J., Regardh, C. G., Gabrielson, M., Löfberg, I., Skanberg, I. (1984): „Determination of omeprazole and metabolites in plasma and urine by high pressure-liquid chromatography“, *Gastroenterology*, 2: 311-319
69. Howden, C. W., Forrest, J. A. H., Reid, J. L. (1984): „Effect of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man“, *Gut*, 25: 707–710
70. Howden, C. W., Meredith, P. A., Forrest, J. A. H., Reid, J. L. (1984): „Oral pharmacokinetics of omeprazole“, *European Journal of Clinical Pharmacology*, 26: 641–643
71. Humphries, H. et al. (1988): „Effect of treatment on *Helicobacter pylori* in peptic disease, a randomised prospective trial“, *Gut*, 29: 279–283
72. Jalling, B., Malmberg, A.-S., Lindman, A., Boreus, L. O. (1972): „Evaluation of a Micromethod for Determination of Antibiotic Concentration in Plasma“, *European Journal of Clinical Pharmacology*, 4: 150–157
73. Juntinen, K., Granberg, C., Häivä, V. M., Lehtonen, O. P., Kujari, H. K., Mansikka, A.: *Evaluation of Poloriset dry latex agglutination test for detection of antibodies to Helicobacter pylori*, Workshop 5.–7.07.1992, Dublin: „Gastroduodenal Pathology and *Helicobacter pylori*“
74. Kayser, S., Flury, R., Zbinden, R. (1997): „Comparative effect of lansoprazole/ amoxicillin with omeprazole/amoxicillin for eradication of *Helicobacter pylori* in patients with duodenal ulcer “ *Schweiz-Med-Wochenschr.*, 127: 722-727
75. Kirby, W. M. M., Gordon, R. C., Regamy, S. (1974): „The pharmacology of orally administered amoxicillin and ampicillin“, *Journal of Infectious Diseases*, 129: 154–155

76. Klein, P.: „Bakteriologische Grundlagen der chemotherapeutischen Laborpraxis“, *Springer*, Berlin/Göttingen/Heidelberg 1957: S.21–27
77. Klein, P. D., Malaty, H. M., Martin, R.-F., Graham, S. K., Graham, D. Y. (1994): „A prospective protocol on performance parameters in the 13-C-Urea Breath Test“, *American Journal of Gastroenterology*, 89: 4720
78. Komjatzny, G. E.: „Die Entzündung des Magens“, in: S. Henke und H. Lubarch (Hrsg.): *Handbuch der speziellen pathologischen Anatomie und Histologie*, 4/2, Springer, Berlin 1928, S. 77–79
79. Konsunen, T. U., Hook, J., Rautelin, H., Myllyla, G. (1989): „Age-dependent increase of Campylobacter pylori antibodies in blood donors“, *Scandinavian Journal of Gastroenterology*, 24: 110–114
80. Konsunen, T. U. und K. Seppälä (1993): „Diagnostic value of different antigens in HP Serology“, *Acta Gastro Enterologica Belgica*, 6. Workshop, 21.–25. 09.1993, Brüssel „Gastroduodenal Pathology and Helicobacter pylori“
81. Konsunen, T. U., Seppälä, K., Sarna, S., Sipponen, P. K. (1992): „Diagnostic value of decreasing IgG, IgA and IgM antibody titres after eradication of Helicobacter pylori“, *Lancet*, 339: 893–895
82. Krauwinkel, W. J. J., Volkens-Kamermans, N. J., van Zijtveld, J. (1993): „Determination of Amoxicillin in human plasma by high-performance liquid chromatography and solid phase extraction“, *Journal of Chromatography*, 617: 334–338
83. Kreuning, I., Lindeman, J., Biemond, I., Lamers, C. B. H. W. (1994): „Relation between IgG and IgA antibody titres against Helicobacter pylori in serum and serverity of gastritis in asymptomatic subjects“, *Journal of Clinical Pathology*, 47: 227–231
84. Labenz, J. und G. Börsch (1994): „Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relaps“, *Digestion*, 55: 19–23
85. Labenz, J., Gyenes, E., Rühl, G. H., Börsch, G. (1993): „Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: A prospective, randomized, and controlled study“, *Gut*, 34: 1167–1170
86. Labenz, J., Gyenes, E. et al. (1993): „Ist die Helicobacter pylori-Gastritis eine makroskopische Diagnose?“, *Deutsche medizinische Wochenschrift*, 118: 6-7

87. Labenz, J., Jorjas, I., Sollbohmer, M., Peitz, U., Stolte, M., Borsch, G. (1994): „24-hour gastric pH pattern in patients with H.pylori associated peptic ulcer disease treated with Omeprazole 20mg bid or 40mg bid“, *Journal of Gastroenterology*, 32: 436–440
88. Labenz, J., Stolte, M., Blum, A. L., Jorjas, J., Sollbohmer, M., Leverkus, F. (1994/ Januar): „24-hour gastric pH-profile with 2x20mg and 2x40mg omeprazole in patients with pylori associated gastroduodenal ulcer disease“, *American Journal of Gastroenterology*, 89: 39–42
89. Labenz, J., Stolte, M., Blum, A.L. et al (1995): „Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin“, *Gut*, 37: 39-43
90. Lagerström, P.-O. und B.-A. Persson (1984): „Determination of omeprazole and metabolites in plasma and urine by liquid chromatography“, *Journal of Chromatography*, 309: 347–356
91. Laine, L., Frantz, J. E., Baker, A. (1997): „A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori.“*Alimental-Pharmacology-Therapy*, 11: 913-917
92. Larsson, H., Carlsson, E., Mattsson, H. et al. (1986): „Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation“, *Gastroenterology*, 90: 391–399
93. Levi, S., Beardshall, K., Swift, I. et al. (1989): „Antral Helicobacter pylori hypergastrinaemia and duodenal ulcers: Effect of eradicating the organism“, *British Medical Journal*, 299: 1504–1505
94. Levi, S., Swift, I. et al. (1989): „Campylobacter pylori and duodenal ulcer: The gastric link“, *Lancet*, 1: 1167–1168
95. Lin, S. K., Lambert, J. R., Schembri, M., Nicholson, L., Johnson, I., Perry, G., Coulepis, A., Korman, M. G. (1992): „Prevalence of Helicobacter pylori in practising dental staff and dental students“, *Gastroenterology*, 102: A 113
96. Lindberg, P., Noedberg, P., Alminger, T., Brandström, A., Wallmar, B. (1986): „The mechanism of action of the gastric secretion inhibitor omeprazole“, *Journal of Medical Chemistry*, 29: 1327–1329

97. Londong, W., Angerer, M., Bosch, R., Koezlow, H. (1990): „Standardization of electrode position and comparison of meals for long-term intragastric pH-Metry in man“, *Digestive Disease*, 8: 46–53
98. Londong, W., Gorgas, R., Pommerien, W. et al. (1995): „Effect of different omeprazole doses combined with amoxicillin on intragastric pH amoxicillin bioavailability and *Helicobacter pylori* eradication in duodenal ulcer patients“, *Gastroenterology*, 108: A-153
99. Londong, W., Londong, V., Cederberg, C., Steffen, H. (1983): „Dose response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release“, *Gastroenterology*, 85: 1373–1378
100. Lopez-Brea, M., Martin, E., Alcarcon, T., Martinez, M. J., Gimeno, D., Sanz, J. C.: *Clinical value of five different methods in the diagnosis of Helicobacter pylori infection in children*, 6. Workshop, September 1993, Brüssel: "Gastroduodenal Pathology and Helicobacter pylori"
101. Lotterer, E., Lüdtke, F. E., Tegler, R., Lepsien, G., Bauer, F. E. (1993): „The 13 C urea breath test-detection of *Helicobacter pylori* infection in patients with partial gastrectomy“, *Zeitschrift für Gastroenterologie*, 31: 115–119
102. Malfertheiner, P.: *Helicobacter pylori – Von der Grundlage zur Therapie*, Georg Thieme Verlag, Stuttgart/New York 1994, S.22–38
103. Malfertheiner, P. (1993): „Compliance, Adverse events and antibiotic resistance in *Helicobacter pylori* Treatment“, *Scandinavian Journal of Gastroenterology*, 28: 34–37
104. Marshall, B. J., Armstrong, J., Mc Gechie, D., Glancy, R. J. (1985): „Attempt to fulfil Koch`s postulates for pyloric *Campylobacter*“, *Medical Journal of Australia*, 142: 436–439
105. Marshall, B. J. und S. R. Langton (1986): „Urea hydrolysis in patients with *Campylobacter pyloridis* infection“, *Lancet*, 1: 965–966
106. Marshall, B. J. und J. R. Warren (1984): „Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration“, *Lancet*, 1: 1311–1315
107. Mc Clendon, J. (1915): „New hydrogen electrodes and rapid methods of determining hydrogen ion concentration“, *American Journal of Physiology*, 38: 180–185

108. Mc Coll, K. E. L., Fullarton, G. M., Chittajaly, R., El Nujumi, A. M., Macdonald, M. I. (1991): „Plasma gastrin, daytime intragastric pH and nocturnal acid output before and at 1 and 7 months after eradication of *Helicobacter pylori* in duodenal ulcer subjects“, *Scandinavian Journal of Gastroenterology*, 26: 339–346
109. Mc Laughlan, G., Fullarton, G. M., Crean, G. P., Mc Coll, K. E. L. (1989): „Comparison of gastric body and antral pH: A 24 h ambulatory study in healthy volunteers“, *Gut*, 30: 573–578
110. Mc Laughlan, G., Rawlings, J. M., Lucas, M. L., Mc Cloy, R. F., Crean, G. P., Mc Coll, K. E. L. (1987): „Electrodes for 24 h pH monitoring – A comparative study“, *Gut*, 28: 935–939
111. Mc Tavish, D., Buckley, M. M. T., Heel, R. C. (1991): „Omeprazole – an updated review of its pharmacology and therapeutic use in acid-related disorders“, *Drugs*, 42: 138–170
112. Merki, H. S., Neumann, J., Kaufmann, D. et al. (1988): „Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer“, *Gut*, 29: 453–457
113. Merki, H., Witzel, L., Harre, K. et al. (1986): „Circadian pattern of intragastric acidity in duodenal ulcer patients. A comparison with healthy controls“, *Gastroenterology*, 90: 1549-1551
114. Merki, H. S., Witzel, L., Walt, R. P., Cohnen, E., Harre, K., Heim, J., Mappes, A., Röhmel, J. (1988): „Day to day variation of 24 h intragastric acidity“, *Gastroenterology*, 94: 887–891
115. Meyer, B., Werth, B., Beglinger, C., Dill, S., Drewe, J., Vischer, W. A., Eggers, R. H., Bauer, F. E. (1991): „*Helicobacter pylori* infection in healthy people: A dynamic process?“, *Gut*, 32: 347–350
116. Miehke, S., Mannes, G.H., Lehn, N. et al (1997): „An increasing doses of omeprazole combined with amoxicillin cures *Helicobacter pylori* infection more effectively.“ *Alimental-Pharmacology-Therapy*, 11: 323-329
117. Mobley, H. T., Cortesa, M. J., Rosenthal, L. E., Jones, B. D. (1988): „Characterizing of Urease from *Campylobacter pylori*“, *Journal of Clinical Microbiology*, 26: 831–836

118. Müller, V. P., Seitz, H. K., Simon, B., Dammann, H. G. (1983): „Säuresekretionsverhalten und Plasmaspiegel unter einer mehrtägigen Omeprazol-Gabe“, *Arzneimittelforschung*, 33: 1685–1686
119. Müller, V. P., Seitz, H. K., Simon, B. et al. (1984): „Vierwöchige Omeprazol-Gabe: Einfluß auf Säureverhalten und basale Hormonspiegel“, *Zeitschrift für Gastroenterologie*, 22: 236–240
120. Naesdal, J., Andersson, T., Bodemar, G. et al. (1986): „Pharmacokinetics of (14 C) omeprazole in patients with impaired renal function“, *Clinical Pharmacology and Therapy*, 40: 344–351
121. Northfield, T. C., Mendall, M., Goggin, P. M.: *Helicobacter pylori infection*, Kluwer Academic Publishers, London 1993, S.33–42
122. Oderda, G., Vaira, D., Hoton, J., Ainley, C., Altare, F., Ansaldi, N. (1989): „Amoxicillin plus trnidazole for Campylobacter pylori gastritis in children: Assessment by serum IgG antibody, pepsinogen I, and gastrin levels“, *Lancet*, 1: 690–692
123. Ormand, J. E. et al. (1991): „Prevalence of Helicobacter pylori in specific forms of gastritis. Further evidence supporting a pathogenetic role for Helicobacter pylori in chronic non-specific gastritis“, *Digestive Disease Science*, 36: 142–145
124. Paintaud, G., Alvan, G., Dahl, M. L., Grahnen, A., Sjövall, J., Svensson, J. O. (1992): „Nonlinearity of amoxicillin absorption kinetics in human“, *Journal of Clinical Pharmacology*, 43: 283–288
125. Paradis, A., Goldie, J., Veldhuyzen van Zanten, S. J. O., Richardsen, H., Hunt, H. R. (1990): „The in vitro inhibitory effect of omeprazole on Helicobacter pylori: a bimodal distribution?“, 3. Workshop of the European Helicobacter study group, 8.–10. November 1990, Toledo (Spanien), *Enfermedades Digestivas*, 78: 113
126. Paulsen, O., Höglund, P., Walder, M. (1989): „No Effect of omeprazole-induced hypoacidity of the bioavailability of amoxicillin or bacampicillin“, *Scandinavian Journal of Infectious Diseases*, 21: 219–223
127. Penston, J. G. (1994): „Helicobacter eradication – understandable caution but no excuse for inertia“, *Alimental Pharmacology Therapy*, 8: 369–389
128. Pilbrand, A. und C. Cederberg (1985): „Development of an oral formulation of omeprazole“, *Scandinavian Journal of Gastroenterology*, 20: 113–120

129. Prichard, P. J., Walt, R. P., Kitchingman, G. K. et al. (1987): „Oral phenytoin pharmacokinetics during omeprazole therapy“, *British Journal of Clinical Pharmacology*, 24: 543–545
130. Prichard, P. J., Yeomans, N. D., Mihaly, G. W. et al. (1985): „Omeprazole: a study of its inhibition of astric pH and oral pharmacokinetics after morning or evening dosage“, *Gastroenterology*, 88: 64–69
131. Regardh, C. G. (1986): „Pharmacokinetics and metabolism in man“, *Scandinavian Journal of Gastroenterology*, 21: 99–104
132. Regardh, C. G., Andersson, T., Lagerström, P. O., Lundborg, P., Skanberg, I. (1990): „The pharmacokinetics of omeprazole in humans – A study of single intravenous and oral doses“, *Therapeutic Drug Monitoring*, 12: 163–172
133. Regardh, C. G., Gabrielsson, M., Hoffmann, K.-J., Löftberg, I., Skanberg, I. (1988): „Pharmacokinetics and metabolism of omeprazole in animals and man – an overview“, *Scandinavian Journal of Gastroenterology*, 20: 79–94
134. Renberg, L., Simonsson, R., Hoffmann, K. J. (1989): „Identification of two main urinary metabolites of (C14)-Omeprazole in humans“, *Metabolism and Disposition*, 17: 69–76
135. Röhmel, J., Merki, H. S. et al. (1990): „Analysis and statistical evaluation of continuous pH-recording“, *Digestive Disease*, 8: 87–96
136. Rune, S. J. (1981): „In vivo investigations by continuous measurements of gastric and duodenal pH“, *Scandinavian Journal of Gastroenterology*, 17: 48–51
137. Rune, S. J., Justesen, T., Hansen, J. M. et al. (1993): „Prevention of duodenal ulcer recurrence with penicillin“, *Scandinavian Journal of Gastroenterology*, 28: 438–442
138. Savarino, V. und G. S Mela (1990): „Comparison of gastric aspiration and continuous pH monitoring with antimony electrode: Methodological remarks“, *Digestive Disease* 33: 23–30
139. Savarino, V., Mela, G. S., Scalabrini, P., Sumberaz, A., Fera, G., Celle, G. (1988): „24 h study of intragastric acidity of duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry“, *Digestive Disease Science*, 33: 1077–1080
140. Savarino, V., Mela, G. S. et al. (1995): „Does circadian gastric acidity differ in Helicobacter pylori positive duodenal ulcer patients with and without duodenal gastric metaplasia?, AGA-Kongreß, A: 340

141. Savarino, V., Mela, S. G., Zantilin, P. et al (1995): „New insight in the mechanism of omeprazole antimicrobial combinations to eradicate *Helicobacter pylori*.“ *American Journal of Gastroenterology*, 90: 673-674
142. Savarino, V., Mela, G. S., Zentilin, P. et al (1996): „The effect of omeprazole 20mg and 40mg twice daily on intragastric acidity in duodenal ulcer patients.“ *Alimentary-Pharmacology-Therapy*, 10: 376-372
143. Schoeller, D. A., Schneider, J. F., Solomons, N. W., Watkins, J. B., Klein, P. D. (1977): „Clinical diagnosis with the stable isotope C¹³ in CO₂ breath tests: Methodology and fundamental considerations“, *Journal of Laboratory Clinical Medicine*, 90: 412–421
144. Sharma, B. K., Walt, R. P., Pounder, R. E., Gomes, F. A., Wood, E. C., Logan, L. H. (1984): „Optimal dose of oral omeprazole for maximal 24 h decrease of intragastric acidity“, *Gut*, 25: 957–964
145. Simon, C. und W. Toeller (1974): „Amoxicillin, ein neues Aminobenzylpenicillin“, *Arzneimittelforschung*, 24: 181
146. Sipponen, P. K. und P. Hyvärinen (1993): „Role of *Helicobacter pylori* in the Pathogenesis of Gastritis, Peptic Ulcer and Gastric Cancer“, *Scandinavian Journal of Gastroenterology*, 28: 3–6
147. Sipponen, P. K., Varis, O., Fraki, U. M., Korri, K., Säppöälä, M., Sirula, M. (1990): „Cumulative 10 years risk of symptomatic duodenal and gastric ulcer in patients with and without gastritis. A clinical follow-up study of 454 patients“, *Scandinavian Journal of Gastroenterology*, 25: 966–973
148. Sjostedt, S., Mostafa, M., Veress, B., Nord, C. E., Seenalu, R. (1994): „Implication of acid suppression in *Helicobacter pylori* treatment: 24h-pH-monitoring before and during treatment with Omeprazole and Amoxicillin“, *The American Journal of Gastroenterology*, 89: 8-11
149. Sommer, D. E. K., van Wyk, M., Moncrieff, J. (1984): „Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cerufoxime axetil“, *British Journal of Clinical Pharmacology*, 18: 535–539
150. Stadelmann, O.: „Gastritis: Erscheinungsformen und klinische Wertigkeit“, in: W. K. Domschke und G. Wormsley (Hrsg.): *Magen- und Darmkrankheiten*, Georg Thieme Verlag, Stuttgart/New York 1981, S.220

151. Suerbaum, S. H., Lying, B., Hemmerle, K., Klemm, K., Opferkuch, W. (1990): „Antibacterial activity of pantoprazole, omeprazole, and other (H+/K+) ATP-ase inhibitors against *Helicobacter pylori*“, 3. Workshop of the European *Helicobacter pylori* study group, 8.–10.11.1990, Toledo (Spanien), *Enfermedades Digestivas*, 78: 134
152. Sung, J. J., Chung, S. C., Ling, T. K. et al (1996): „dualtherapy versus triple therapy for *Helicobacter pylori*-associated duodenal ulcers. *Digestive Diseases and Sciences*, 41: 453-457
153. Sutherland, R., Croyden, P., Rollinson, G. N. (1972): „Amoxicillin: A new semisynthetic penicillin“, *British Medical Journal*, 3: 13–16
154. Talley, N. J. (1988): „*Campylobacter pylori*-associated gastritis. Is an antibiotic therapy now justified?“, *Journal of Clinical Gastroenterology*, 10: 10–12
155. Thijis, J. C., van-Zwet, A. A., Mollenaar, W. et al (1996): „Tripletherapy versus amoxicillin plus omeprazole for treatment of *Helicobacter pylori* infection: a multicenter, prospective, randomized controlled study of efficacy and side effects.“ *American Journal of Gastroenterology*, 91:93-97
156. Thomas, J. E., Whatmore, A. M., Barer, M. R. et al. (1990): „Serodiagnosis of *Helicobacter pylori* Infection in Childhood“, *Journal of Clinical Microbiology*, 27: 2641–2646
157. Treiber, G. und U. Klotz (1994): „*Helicobacter pylori* eradication rates do not depend on higher omeprazole plasma levels“, *American Journal of Gastroenterology*, 89: 8-9
158. Tschink, G.: „*Der Einfluß von Pirenzepin auf die Bioverfügbarkeit von Amoxicillin, Cephalexin und Doxycycli*“, Inaugural-Dissertation an der FU-Berlin, 1988, S.39–52
159. Tygat, G. N., Langenberg, M. L., Schnipper, M. E. I. et al. (1984): „*Campylobacterlike* organism in the stomach of patients and healthy individuals“, *Lancet*, 1: 1348-1351
160. Mc Tavish, D., Buckley, M. M. T., Heel, R. C. (1991): „Omeprazole – an updated review of its pharmacology and therapeutic use in acid-related disorders“, *Drugs*, 42: 138–170
161. Tuynman, H. A. R. E., Festen, H. P. M., Röhss, K., Meuwissen, S. G. M. (1987): „Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules“, *British Journal of Clinical Gastroenterology*, 24: 833–835

162. Unge, P. und T. Ekström (1993): „Effects of Combination Therapy with Omeprazole and an antibiotic on *Helicobacter pylori* and duodenal ulcer disease“, *Scandinavian Journal of Gastroenterology*, 28: 17–18
163. Unge, P., Eriksson, K., Bergmann, B. et al. (1992): „Omeprazole and amoxicillin in patients with duodenal ulcer: *H.pylori* eradication and remission of ulcers and symptoms during 6 months follow-up“, *Gastroenterology*, 102: A 38
164. Unge, P., Gad, A., Eriksson, K. et al. (1993): „Amoxicillin added to omeprazole prevents relaps on the treatment of duodenal ulcer patients“, *European Journal of Gastroenterology and Hepatology*, 5: 325–331
165. Veendaal, R. A., Pena, A.-S., Meijer, J.-S., Endtz, M., van der Est, M. M. C., van Duijn, W., Euldenrink, F., Kreuning, J., Lamers, S. B. H. (1991): „Long-term serological surveillance after treatment of *Helicobacter pylori* infection“, *Gut*, 32: 1291–1294
166. Verdú, E. F., Armstrong, D., Fraser, R. et al (1995): „Effect of *Helicobacter pylori* status on intragastric pH during treatment with omeprazole“, *Gut*, 36: 539-543
167. Verdú, E. F., Armstrong, D., Idström, J. P. et al (1995): „ Effect of curing *Helicobacter pylori* infection on intragastric pH during treatment with omeprazole“, *Gut*, 37:743-748
168. Verdú, E. F., Armstrong, D., Idström, J. P. et al: „Intragastric pH during treatment with omeprazole: role of *Helicobacter pylori* and *H.pylori*-associated gastritis“, *Scandinavian Journal of Gastroenterology*, 31:1151-1156
169. Wagner, S. (1991): „Bedeutung der Langzeit-pH-Metrie in der Diagnostik säurebedingter Erkrankungen“, *Arzt und Krankenhaus*, 6: 177–1181
170. Wagner, S., Feise, J., Schmidt, F. W. (1988): „H₂-Receptor antagonist nonresponder“, *Lancet*, 1: 128-132
171. Wagner, S., Gladziwa, U., Gebel, M., Schüler, A., Freise, J., Schmidt, F. W. (1991): „Circadian pattern of intragastric acidity in duodenal ulcer patients: A study of variations in relation to ulcer acidity“, *Gut*, 32: 1104–1109
172. Wagner, S., Gladziwa, U., Lange, P., Gebel, M., Schmidt, F. W. (1991): „Intragastrale Langzeit-pH-Metrie: Welche Rolle spielt die Wahl der Elektrode?“, *Klinische Wochenschrift*, 69: 38-41
173. Wallmark, B. (1986): „Mechanism of action of omeprazole“, *Scandinavian Journal of Gastroenterology*, 21: 11–17

174. Wallmark, B., Brandström, A., Larsson, H. (1984): „Evidence for acid-induced transformation of omeprazole into an active inhibitor of H/K-ATP-ase within the partial cell“, *Biochim. Biophys. Acta*, 778: 549–558
175. Wallmark, B., Skanberg, I., Mattson, H. et al. (1990): „Effect of 20 weeks ranitidine treatment on plasma gastrin levels and gastric enterochromaffin-like cell density in the rat“, *Digestion*, 45: 181–182
176. Walter, A. und M. Walter (1958): „Eine Mikromethode geeignet zur Bestimmung von Blut-Konzentrationen der meisten gebräuchlichen Antibiotika“, *Zeitschrift für Hygiene*, 145: 320–330
177. Warren, J. R. (1983): „Unidentified curved bacilli on gastric epithelium in active chronic gastritis“, *Lancet*, 2: 1273-1274
178. Weil, J., Bell, G. D., Jones, P. H., Gant, P., Trowell, J. E., Harrison, G. (1988): „Eradication of *Campylobacter pylori*: are we being misled?“, *Lancet*, 2: 1245
179. Westerbloom, T. U.: „The comparative value of different diagnostic tests for *Helicobacter pylori*“, in: C. S. Goodwin and B. W. Worsely (Hrsg.): *Helicobacter pylori – Biology and clinical Practice*, CRC Press, 1993: S.329–342
180. Westerbloom, T. U. und D. E. Duriex (1990): „H₂-blockers increase antibiotic concentrations in gastric mucosa“, 3.Workshop of the European *Helicobacter pylori* study group, 8.–10. 11.1990, Toledo (Spanien), *Enfermedades Digestivas*, 78: 136
181. Westerbloom, T. U., Madan, E., Gudipati, S., Midkiff, B. R., Czinn, J. S. (1992): „Diagnosis of *Helicobacter pylori*-infection in adult and pediatric patients by using Pyloriset, a rapid latex agglutinationtest“, *Journal of Clinical Microbiology*, 30: 96–98
182. Westerbloom, T. U., Madan, E., Kemp, J., Subik, M. A. (1988): „Evaluation of Rapid Urease Test to Detect *Campylobacter pylori*-Infection“, *Journal of Clinical Microbiology*, 24: 1393–1394
183. Wyatt, J. J.: „*Campylobacter pylori*, duodenitis and duodenal ulceration“, in: B. J. Rathbone und R. V. Heaty (Hrsg.): *Campylobacter pylori and Gastroduodenal disease*, Blackwell Scientific Publication, Victoria (Australien) 1989: S.117–124
184. Wyatt, J. J. und M. F. Dixon (1988): „Chronic gastritis – a pharmacogenetic approach“, *Journal of Pathology*, 154: 113–124

9. Veröffentlichungen

In folgenden Veröffentlichungen sind Teile der hier vorliegenden Dissertation publiziert worden:

1. Pommerien, W.; Braun, M.; Idstrom, J. P.; Wrangstadh, M.; Londong, W.: „No pharmacokinetic interaction between omeprazole and amoxicillin during combination therapie in helicobacter pylori positive haelthy subjects“ AGA Congress / DDW Scientific Session 16.05.1995; abstract and poster, 2088: A-522
2. Pommerien, W.; Braun, M.; Idstrom, J. P.; Wrangstadh, M.; Londong, W. (1996): „Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxicillin in helicobacter pylori positive haelthy subjects“ *Alimental Pharmacology Therapy*; 10:295-301